Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
By R. Maini, P. Taylor, J. Szechiński, K. Pavelka, J. Broll, G. Bálint, P. Emery, F. Raemen, J. Petersen, J. Smolen and 2 more. Arthritis & Rheumatism, 2006
762 citations recorded by the source corpus.
Subfields: Rheumatology
View Paper: https://www.semanticscholar.org/paper/11c1551d2c7fa0a3c5ddb679411e255379f8a3dd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Rheumatology
Citations in the corpus
- Muscles and their myokines (2011, background): “In addition, changes in lipid profiles were also seen in patients with rheumatoid arthritis receiving IL-6 blocking treatment (Nishimoto et al., 2004; Maini et al., 2006; Smolen et al., 2008).”
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010, neutral): “both on the basis of its efficacy as monotherapy and on the basis of its ability to increase the efficacy of biological DMARDs when used in combination,”
- TH-17 cells in the circle of immunity and autoimmunity (2007, background): “Thus, it is not unexpected that therapy with antibody to IL-6R is showing great promise in the treatment of rheumatoid arthritis and juvenile rheumatoid arthriti”
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010, neutral): “2 53 MTX is considered the anchor drug in RA, 54 both on the basis of its effi cacy as monotherapy and on the basis of its ability to increase the effi cacy of biological DMARDs when used in combination, 55–59 as well as the benefi cial long-term safety profi le.”
- Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review (2008, background): “]) and, possibly, use of selective IL-6 antagonists in early randomized trials [”